The data are early but de-risk the FT836 program and validate the Sword & Shield platform in solid tumors without conditioning chemo, a key differentiator. However, with only 2 efficacy-evaluable patients showing activity, the stock may see a modest positive move on proof-of-concept but faces binary risk from future enrollment expansion and durability data. Monitor for next data update and potential partnership interest.
FATE drugs
FATE drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 1 $2.74entry
- T+1 · 6mo ago −6.20%α −6.35% · $2.57
- T+5 · 5mo ago −27.74%α −24.99% · $1.98
- T+20 · 5mo ago −1.46%α −0.16% · $2.70
- T+60 · 3mo ago −6.93%α −8.17% · $2.55
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Fate Therapeutics presented early Phase 1 data for FT836, an off-the-shelf CAR T-cell therapy targeting MICA/B in solid tumors, at ASCO 2026. In two heavily pre-treated KRASwt metastatic colorectal cancer patients, FT836 plus cetuximab without conditioning chemotherapy showed a 19% tumor reduction (Case 1) and a 52% liver lesion reduction (Case 2), with no DLTs, CRS, ICANS, or GvHD across nine patients. The data demonstrate first-in-human proof of trafficking and persistence in tumor tissue without lymphodepletion, but the sample is tiny (n=9 safety, n=5 efficacy-evaluable, n=2 with anti-tumor activity) and early-stage, limiting immediate stock-moving impact.
Key Facts
- FT836 is an off-the-shelf, iPSC-derived CAR T-cell targeting MICA/B with Sword & Shield technology to eliminate need for conditioning chemotherapy.
- Nine patients enrolled across two regimens (FT836 + cetuximab, n=6; FT836 + trastuzumab, n=3); no DLTs, CRS, ICANS, or GvHD observed.
- Five patients available for efficacy; two KRASwt mCRC patients with 7 prior lines each showed tumor reduction: 19% sum-of-diameters (Case 1) and 52% liver lesion reduction (Case 2).
- FT836 detected in peripheral blood (peak Day 4) and tumor tissue (Day 22 biopsy) without conditioning chemotherapy, with evidence of tumor immune microenvironment remodeling.
- Company plans to focus on CRC patient population based on these results.
- Market cap ~$331M; analyst consensus 61% bullish (11 Buy, 7 Hold).
Financial Impact
No financial data provided; early-stage clinical data with no revenue or guidance impact.
Risk Factors
- Extremely small sample size (n=2 efficacy-evaluable with anti-tumor activity); results may not replicate in larger cohorts.
- No conditioning chemotherapy may limit CAR T persistence in broader patient populations; durability data are immature.
- Company is pre-revenue with no approved products; cash runway and financing risk remain.
- Competitive landscape includes multiple off-the-shelf CAR T and bispecific approaches in solid tumors.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304368 |
Track record
21 reports on FATE
4 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 13, 20264d ago EFFECT Bearish 5/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 12, 20264d ago 424B5 Bearish 4/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 9, 20267d ago SC 13D/A Neutral 2/10 Entry $1.77 Now $1.14 −35.59% settles Nov 17
- Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers